Heron Therapeutics (HRTX) Change in Accured Expenses (2010 - 2026)

Heron Therapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at -$2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 7.19% year-over-year to -$2.9 million; the trailing twelve-month figure through Mar 2026 stood at $10.8 million (up 858.44% YoY), and the FY2025 full-year result was $10.6 million, up 10607.07% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.9 million, down from $3.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $13.5 million in Q4 2022, with the low at -$3.9 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $972058.8 across 5 years, with a median of $346000.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 1910.63% — and 2024, when it plunged 329.81%.
• Heron Therapeutics' Change in Accured Expenses stood at $13.5 million in 2022, then sank by 108.56% to -$1.2 million in 2023, then soared by 168.75% to $792000.0 in 2024, then jumped by 347.98% to $3.5 million in 2025, then plunged by 181.17% to -$2.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.9 million (Q1 2026), $3.5 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.